Annexin 1 antibody
View Patent ↗The present invention provides a specific binding molecule raised against the human Anx-A1 protein having the amino acid sequence shown in FIG. 2 A. The present invention also relates to the sue of such a specific binding molecule in the treatment of T cell-mediated disease.
1. An antibody or fragment thereof that binds human Anx-A1 having the amino acid sequence of SEQ ID NO:8, said antibody or fragment thereof comprising Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which
VLCDR1 is KASENVVTYVS (SEQ ID NO:2)
VLCDR2 is GASNRYT (SEQ ID NO:3)
VLCDR3 is GQGYSYPYT (SEQ ID NO:4)
VHCDR1 is GYTFTNYWIG (SEQ ID NO:5)
VHCDR2 is DIYPGGDYTNYNEKFKG (SEQ ID NO:6)
VHCDR3 is WGLGYYFDY (SEQ ID NO:7)
of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301.
2. An antibody or fragment thereof as claimed in claim 1 wherein the antibody is a monoclonal antibody.
3. An antibody or fragment thereof as claimed in claim 2 wherein the monoclonal antibody is humanized.
4. An antibody or fragment thereof as claimed in claim 1 wherein the fragment is a Fab, F(ab′) 2 or Fv fragment or an scFv molecule.
5. An antibody or fragment thereof as claimed in claim 1 comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:19 and/or a light chain variable region having the amino acid sequence of SEQ ID NO:15.
6. An antibody or fragment thereof as claimed in claim 1 produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301, wherein the antibody is a humanized monoclonal antibody.
7. A hybridoma cell line which produces an antibody or fragment thereof that binds the human Anx-A1 protein having the amino acid sequence of SEQ ID NO:8, said antibody or fragment thereof comprising wherein the antibody comprises Complementarity Determining Regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which
VLCDR1 is KASENVVTYVS, (SEQ ID NO:2)
VLCDR2 is GASNRYT, (SEQ ID NO:3)
VLCDR3 is GQGYSYPYT, (SEQ ID NO:4)
VHCDR1 is GYTFTNYWIG, (SEQ ID NO:5)
VHCDR2 is DIYPGGDYTNYNEKFKG, and (SEQ ID NO:6)
VHCDR3 is WGLGYYFDY (SEQ ID NO:7)
of an antibody produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301.
8. A hybridoma cell line as claimed in claim 7 deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301.
9. A pharmaceutical composition comprising an antibody or fragment thereof as claimed in claim 1 .
10. A pharmaceutical composition as claimed in claim 9 , further comprising another therapeutically active agent.
11. An antibody or fragment thereof as claimed in claim 1, wherein the antibody comprises:
a light chain variable region produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301; and
a heavy chain variable region comprising Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which:
VHCDR1 is GYTFTNYWIG (SEQ ID NO:5),
VHCDR2 is DIYPGGDYTNYNEKFKG (SEQ ID NO:6), and
VHCDR3 is WGLGYYFDY (SEQ ID NO:7).
12. A humanized antibody comprising the fragment of the antibody as claimed in claim 11, wherein the fragment comprises the CDRs of the antibody defined in claim 11.
13. A hybridoma cell line as claimed in claim 7, wherein the antibody comprises:
a light chain variable region produced by the hybridoma cell line deposited with the European Collection of Cell Cultures (ECACC) on 3 Jun. 2010 as Accession No. 10060301; and
a heavy chain variable region comprising Complementarity Determining Regions (CDRs) VHCDR1, VHCDR2 and VHCDR3, each having a respective amino acid sequence as follows in which:
VHCDR1 is GYTFTNYWIG (SEQ ID NO:5),
VHCDR2 is DIYPGGDYTNYNEKFKG (SEQ ID NO:6), and
VHCDR3 is WGLGYYFDY (SEQ ID NO:7).